Parallel Comparison of 18 Gene Classifiers and Oncotype DX (Nanostring)

NCT03772197 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 138

Last updated 2018-12-19

No results posted yet for this study

Summary

A recurrence index for distant recurrence (RI-DR), an 18-gene-based clinical-genomic model, has been developed for early-stage breast cancer (EBC). In this study, Investigators compared the prognostic performance of the RI-DR with the Oncotype DX (ODx) recurrence score (RS) for any recurrence risk type.

Conditions

Sponsors & Collaborators

  • Amwise Diagnostics Pte. Ltd.

    lead INDUSTRY

Principal Investigators

  • Skye Cheng · AMWISE DIAGNOSTICS PTE. LDT.

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2018-10-18
Completion
2018-11-01

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03772197 on ClinicalTrials.gov